Creating advanced 3D pancreatic tissues from stem cells
Genetically Programmed Pancreatic Organoids with Self-Adaptive Multi-Lineage Population Control
['FUNDING_R01'] · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · NIH-10914047
This study is working on creating tiny, lab-grown versions of the pancreas using special cells from people, which could help us better understand pancreatic diseases and find new treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-10914047 on ClinicalTrials.gov |
What this research studies
This research focuses on developing genetically programmed pancreatic organoids, which are 3D tissues created from human stem cells. By reprogramming adult cells, such as fibroblasts, into induced pluripotent stem cells, the project aims to overcome current limitations in organoid production that rely on external growth factors. The goal is to create organoids that accurately mimic the functionality of real pancreatic tissues, which could be used for studying diseases and testing new treatments. The research combines techniques from synthetic biology and developmental biology to improve the precision and quality of these organoids.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with pancreatic disorders or those interested in contributing to advancements in pancreatic disease treatment.
Not a fit: Patients with conditions unrelated to pancreatic function or those who are not eligible for stem cell-derived therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic diseases by providing better models for drug testing and disease understanding.
How similar studies have performed: Previous research has shown promise in using genetic programming for organoid development, indicating potential success for this innovative approach.
Where this research is happening
CAMBRIDGE, UNITED STATES
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WEISS, RON — MASSACHUSETTS INSTITUTE OF TECHNOLOGY
- Study coordinator: WEISS, RON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.